Abbott Laboratories (ABT) Business News

Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more

  • Calendar
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:00 AM | Monday | Nov 2, 2026 PRNewsWire

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

News Thumbnail
3:45 PM | Sunday | Nov 1, 2026 PRNewsWire

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

News Thumbnail
9:00 AM | Thursday | Oct 29, 2026 PRNewsWire

Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease

News Thumbnail
9:00 AM | Monday | Oct 26, 2026 PRNewsWire

Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment

News Thumbnail
9:15 AM | Friday | Oct 23, 2026 PRNewsWire

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

News Thumbnail
7:30 AM | Wednesday | Oct 21, 2026 PRNewsWire

Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

News Thumbnail
7:25 AM | Wednesday | Oct 21, 2026 PRNewsWire

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

News Thumbnail
9:00 AM | Wednesday | Oct 7, 2026 PRNewsWire

Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop

News Thumbnail
9:00 AM | Monday | Oct 5, 2026 PRNewsWire

Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition

News Thumbnail
9:00 AM | Wednesday | Sep 30, 2026 PRNewsWire

Abbott hosts conference call for third-quarter earnings

News Thumbnail
news photo
Loading...

Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved high closure rates of the left atrial appendage (LAA) and a low incidence of stroke Abbott's Amulet 360™ LAA Occluder is a next-generation device designed to reduce the risk of stroke and other serious blood clot-related complications in people with atrial fibrillation not caused by a heart valve issue ABBOTT PARK, Ill., Nov. 2, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today one-year results for its investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder from the VERITAS study, which show meaningful closure rates of the left atrial appendage and a low incidence of stroke in people with atrial fibrillation (AFib) not caused by a heart valve issue.

Read full article redirect
9:00 AM | Monday | Nov 2, 2026

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

PRNewsWire

Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved high closure rates of the left atrial appendage (LAA) and a low incidence of stroke Abbott's Amulet 360™ LAA Occluder is a next-generation device designed to reduce the risk of stroke and other serious blood clot-related complications in people with atrial fibrillation not caused by a heart valve issue ABBOTT PARK, Ill., Nov. 2, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today one-year results for its investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder from the VERITAS study, which show meaningful closure rates of the left atrial appendage and a low incidence of stroke in people with atrial fibrillation (AFib) not... Read more

Read full article arrow
News Thumbnail
3:45 PM | Sunday | Nov 1, 2026

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

PRNewsWire

SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore blood flow The system is designed to bring purposeful innovation to treating complex coronary calcium, with longer treatment lengths, more pulses and enhanced catheter deliverability Approval of the investigational system would further strengthen Abbott's comprehensive coronary devices portfolio, complementing its advanced imaging, lesion preparation and stent technologies ABBOTT PARK, Ill., Nov. 1, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced strong 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular Lithotripsy (IVL) Investigational Device Exemption (IDE) Study evaluating the use of its investigational SonicForceTM Coronary IVL System, which is designed to crack calcium buildup in coronary... Read more

Read full article arrow
News Thumbnail
9:00 AM | Thursday | Oct 29, 2026

Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease

PRNewsWire

CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option for treating mitral valve disease, the most common type of heart valve ailment 30-day early feasibility study results for Cephea will be presented at TCT 2026 ABBOTT PARK, Ill., Oct. 29, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people with symptomatic mitral valve disease who are not candidates for surgery and transcatheter repair.

Read full article arrow
News Thumbnail
9:00 AM | Monday | Oct 26, 2026

Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment

PRNewsWire

Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs 1, 2, 3 The next-generation Oncodetect test builds on more than 20 years of trusted leadership in using genomic information to personalize cancer care  Modeling estimates more than 3 million U.S. patients with solid tumors could potentially benefit from MRD testing † ABBOTT PARK, Ill., Oct. 26, 2026 /PRNewswire/ -- For many people with cancer, completing treatment can bring a new uncertainty: Is my cancer really gone?

Read full article arrow
News Thumbnail
9:15 AM | Friday | Oct 23, 2026

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

PRNewsWire

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer screening with the Cologuard ® test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoring ABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain.

Read full article arrow
News Thumbnail
7:30 AM | Wednesday | Oct 21, 2026

Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

PRNewsWire

Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 Expands portfolio with key new product approvals ABBOTT PARK, Ill.
, Oct. 21, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept.

Read full article arrow
News Thumbnail
7:25 AM | Wednesday | Oct 21, 2026

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

PRNewsWire

Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies The new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a portfolio of iconic, category-leading brands, including Similac, PediaSure, Pedialyte, Glucerna and Ensure Abbott will have accelerated sales growth and an expanded margin profile Abbott intends to separate its Nutrition business through a tax-free distribution to Abbott shareholders Separation expected to be completed by the end of 2027 ABBOTT PARK, Ill., Oct. 21, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced its intention to separate its Nutrition business into an independent, publicly traded company that will be a global leader in the rapidly expanding healthy nutrition market with approximately $8.5 billion in annual sales and a... Read more

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | Oct 7, 2026

Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop

PRNewsWire

New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate) to help preserve muscle Ensure Max Protein 3-in-1 formula provides muscle support in a single daily serving to support muscle health goals—and is available in chocolate and vanilla at major U.S. retailers Muscle-supporting ingredients like creatine and HMB are moving beyond the gym and into mainstream wellness routines as more adults prioritize strength and fitness ABBOTT PARK, Ill., Oct. 7, 2026 /PRNewswire/ -- Muscle support just got simpler.

Read full article arrow
News Thumbnail
9:00 AM | Monday | Oct 5, 2026

Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition

PRNewsWire

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart failure weeks before patients experience symptoms New capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visits ABBOTT PARK, Ill., Oct. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.
S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | Sep 30, 2026

Abbott hosts conference call for third-quarter earnings

PRNewsWire

ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens.

Read full article arrow
News Thumbnail